Cargando…
Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches
Anticytotoxic T lymphocyte-associated protein 4 (CTLA4) antibodies have shown potent antitumor activity, but systemic immune activation leads to severe immune-related adverse events, limiting clinical usage. We developed novel, conditionally active biologic (CAB) anti-CTLA4 antibodies that are activ...
Autores principales: | Chang, Hwai Wen, Frey, Gerhard, Liu, Haizhen, Xing, Charles, Steinman, Lawrence, Boyle, William J., Short, Jay M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936328/ https://www.ncbi.nlm.nih.gov/pubmed/33627407 http://dx.doi.org/10.1073/pnas.2020606118 |
Ejemplares similares
-
An anti-CTLA-4 heavy chain–only antibody with enhanced T(reg) depletion shows excellent preclinical efficacy and safety profile
por: Gan, Xin, et al.
Publicado: (2022) -
Acoustofluidic Chemical Waveform Generator and Switch
por: Ahmed, Daniel, et al.
Publicado: (2014) -
Anti–CTLA-4 therapy requires an Fc domain for efficacy
por: Ingram, Jessica R., et al.
Publicado: (2018) -
CTLA-4 antibody ipilimumab negatively affects CD4(+) T-cell responses in vitro
por: Rosskopf, Sandra, et al.
Publicado: (2019) -
Constitutive Clathrin-mediated Endocytosis of CTLA-4 Persists during T Cell Activation
por: Qureshi, Omar S., et al.
Publicado: (2012)